GoodRx (GDRX) Competitors $4.31 +0.07 (+1.65%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GDRX vs. DADA, FIVN, RNG, ATHM, QXO, ETSY, NVEI, TNET, ALIT, and PAYOShould you be buying GoodRx stock or one of its competitors? The main competitors of GoodRx include Dada Nexus (DADA), Five9 (FIVN), RingCentral (RNG), Autohome (ATHM), QXO (QXO), Etsy (ETSY), Nuvei (NVEI), TriNet Group (TNET), Alight (ALIT), and Payoneer Global (PAYO). GoodRx vs. Dada Nexus Five9 RingCentral Autohome QXO Etsy Nuvei TriNet Group Alight Payoneer Global Dada Nexus (NASDAQ:DADA) and GoodRx (NASDAQ:GDRX) are both small-cap business services companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings. Do insiders and institutionals hold more shares of DADA or GDRX? 59.3% of Dada Nexus shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 8.5% of Dada Nexus shares are owned by insiders. Comparatively, 4.2% of GoodRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer DADA or GDRX? GoodRx received 36 more outperform votes than Dada Nexus when rated by MarketBeat users. However, 49.28% of users gave Dada Nexus an outperform vote while only 39.33% of users gave GoodRx an outperform vote. CompanyUnderperformOutperformDada NexusOutperform Votes3449.28% Underperform Votes3550.72% GoodRxOutperform Votes7039.33% Underperform Votes10860.67% Do analysts prefer DADA or GDRX? Dada Nexus presently has a consensus price target of $2.70, indicating a potential upside of 88.81%. GoodRx has a consensus price target of $8.86, indicating a potential upside of 105.50%. Given GoodRx's stronger consensus rating and higher possible upside, analysts clearly believe GoodRx is more favorable than Dada Nexus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dada Nexus 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17GoodRx 1 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.67 Which has preferable valuation & earnings, DADA or GDRX? GoodRx has lower revenue, but higher earnings than Dada Nexus. GoodRx is trading at a lower price-to-earnings ratio than Dada Nexus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDada Nexus$1.49B0.25-$275.71M-$1.11-1.29GoodRx$750.27M2.19-$8.87M-$0.03-143.67 Does the media prefer DADA or GDRX? In the previous week, Dada Nexus had 6 more articles in the media than GoodRx. MarketBeat recorded 9 mentions for Dada Nexus and 3 mentions for GoodRx. GoodRx's average media sentiment score of 0.24 beat Dada Nexus' score of 0.02 indicating that GoodRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dada Nexus 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral GoodRx 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is DADA or GDRX more profitable? GoodRx has a net margin of -2.05% compared to Dada Nexus' net margin of -20.95%. GoodRx's return on equity of 5.35% beat Dada Nexus' return on equity.Company Net Margins Return on Equity Return on Assets Dada Nexus-20.95% -12.70% -9.56% GoodRx -2.05%5.35%2.51% Which has more risk and volatility, DADA or GDRX? Dada Nexus has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, GoodRx has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. SummaryGoodRx beats Dada Nexus on 13 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get GoodRx News Delivered to You Automatically Sign up to receive the latest news and ratings for GDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GDRX vs. The Competition Export to ExcelMetricGoodRxData processing & preparation IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.64B$4.34B$5.05B$8.82BDividend YieldN/A3.07%5.17%4.07%P/E Ratio-143.6734.39125.0817.74Price / Sales2.085.271,182.0574.25Price / Cash10.0530.1633.7232.53Price / Book2.236.174.684.68Net Income-$8.87M$42.17M$119.45M$226.08M7 Day Performance-7.51%-3.23%-2.46%-2.03%1 Month Performance-37.63%3.16%-4.08%0.07%1 Year Performance-25.17%6.23%29.81%24.61% GoodRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GDRXGoodRx3.0932 of 5 stars$4.31+1.7%$8.86+105.5%-25.2%$1.64B$750.27M-143.67950DADADada Nexus2.4787 of 5 stars$1.43+2.1%$2.70+88.8%-65.1%$371.51M$1.49B0.002,376Gap UpFIVNFive94.0332 of 5 stars$38.96+2.5%$59.22+52.0%-49.1%$2.93B$910.49M-76.002,684Options VolumeRNGRingCentral4.6018 of 5 stars$35.00-0.1%$40.73+16.4%+15.5%$3.17B$2.36B-33.044,084ATHMAutohome2.0193 of 5 stars$28.53+4.7%$28.00-1.9%+2.5%$3.46B$1.01B14.195,511Analyst DowngradeQXOQXO0.9892 of 5 stars$15.99+0.6%N/AN/A$6.55B$54.52M-1.75195News CoverageETSYEtsy4.6099 of 5 stars$51.66+1.6%$64.87+25.6%-29.4%$5.81B$2.75B25.952,420NVEINuvei1.6818 of 5 stars$33.99+0.0%$32.08-5.6%+72.3%$4.82B$1.19B226.602,202Dividend AnnouncementHigh Trading VolumeTNETTriNet Group4.2848 of 5 stars$94.24+5.8%$117.00+24.2%-15.2%$4.67B$4.97B18.163,600Analyst ForecastPositive NewsALITAlight3.5171 of 5 stars$7.74-0.1%$10.95+41.5%+3.4%$4.23B$3.41B-16.1418,000Insider TradePAYOPayoneer Global4.1831 of 5 stars$10.90+0.5%$10.79-1.0%+99.4%$3.89B$831.10M31.002,167Insider Trade Related Companies and Tools Related Companies Dada Nexus Competitors Five9 Competitors RingCentral Competitors Autohome Competitors QXO Competitors Etsy Competitors Nuvei Competitors TriNet Group Competitors Alight Competitors Payoneer Global Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GDRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GoodRx Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GoodRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
